Initial results from a clinical study suggest that a new gene-based therapy may help alleviate the debilitating symptoms of Parkinson’s disease, illuminating a potential reprieve from tremors, limb stiffness, and loss of balance for the millions of people living with the neurodegenerative disorder.
The new drug ProSavin was shown in a phase I trial to bring about significant improvements in motor function for all participants without considerable side-effects. According to its developers, the drug offers relief by targeting the so-called dopamine deficiency that spurs the development of stiffness and tremors in patients. Kyriacos Mitrophanous, head of research at Oxford BioMedica and senior author of an accompanying study, wrote in an email to Medical Daily that the drug is the first of its kind. Read more at http://www.medicaldaily.com/new-drug-prosavin-offers-parkinsons-symptoms-relief-phase-i-trial-266739